<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="114" measure-type="hr" measure-number="3250" measure-id="id114hr3250" originChamber="HOUSE" orig-publish-date="2015-07-28" update-date="2016-07-19">
<title>DXM Abuse Prevention Act of 2015</title>
<summary summary-id="id114hr3250v79" currentChamber="HOUSE" update-date="2016-07-19">
<action-date>2016-07-08</action-date>
<action-desc>Reported to House without amendment</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)</p> <p><b>DXM Abuse Prevention Act of 2015</b></p> <p>(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the sale of a drug containing dextromethorphan (DXM, a cough suppressant and drug of abuse) to an individual under age 18 unless the individual has a prescription or is actively enrolled in the military. Retailers selling DXM must implement a verification system to ensure compliance. Civil monetary penalties that escalate upon repeated violation are imposed.</p> <p>(Sec. 3) Unfinished DXM may only be possessed by, distributed to, and received by persons registered with the Food and Drug Administration as producers of a drug or medical device or otherwise allowed to engage in the practice of pharmacy, pharmaceutical production, or manufacture or distribution of drug ingredients. Common carriers distributing unfinished DXM between authorized persons are exempted. Civil monetary penalties are imposed for possession and distribution violations. <p>]]></summary-text>
</summary>
<summary summary-id="id114hr3250v00" currentChamber="HOUSE" update-date="2016-01-04">
<action-date>2015-07-28</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p><b>DXM Abuse Prevention Act of 2015</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the sale of a drug containing dextromethorphan (DXM) to an individual under age 18 unless the individual has a prescription or is actively enrolled in the military. Civil monetary penalties that escalate upon repeated violation are imposed.</p> <p> <p>To possess or receive unfinished DXM, a person must be registered with the Department of Health and Human Services as a producer of a drug or medical device or otherwise allowed to engage in the practice of pharmacy, pharmaceutical production, or manufacture or distribution of drug ingredients. Unfinished DXM may be distributed only to these authorized persons. Common carriers distributing unfinished DXM between authorized persons are exempted. Civil monetary penalties are imposed for possession and distribution violations. <p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
